Monitoring and management of adverse reactions to pegylated interferon alpha-2b for treatment of chronic hepatitis B
- VernacularTitle:慢性乙型肝炎患者聚乙二醇干扰素α-2b治疗过程中不良反应的监测与管理
- Author:
Xinyi LI
1
;
Weijiang YE
2
;
Danlei CHEN
1
;
Jiawei ZHANG
1
Author Information
- Publication Type:Review
- Keywords: Pegylated Interferon; Chronic Hepatitis B; Drug-Related Side Effects and Adverse Reactions
- From: Journal of Clinical Hepatology 2026;42(2):414-419
- CountryChina
- Language:Chinese
- Abstract: Pegylated interferon α-2b （PEG-IFN-α-2b） is currently a first-line drug for the treatment of chronic hepatitis B virus infection and is widely used in clinical practice. This drug has multiple effects of inhibiting viral replication， regulating immunity， and improving liver function， and some patients can achieve clinical cure. However， it often causes various adverse reactions during treatment， which are important factors for compromising treatment compliance and efficacy. This article systematically reviews the adverse reactions and their mechanisms during PEG-IFN-α-2b therapy for chronic hepatitis B， including influenza-like symptoms， peripheral blood cytopenia， thyroid dysfunction， and neuropsychiatric symptoms， and it also summarizes the monitoring and management strategies for these adverse reactions， in order to provide evidence-based guidance for clinical decision-making and emphasize the importance of individualized treatment.
